Comparison of drug eluting versus bare metal stents for pulmonary vein stenosis in childhood

Catheter Cardiovasc Interv. 2019 Aug 1;94(2):233-242. doi: 10.1002/ccd.28328. Epub 2019 May 8.

Abstract

Objective: Comparison of outcomes using bare metal (BMS) and drug-eluting (DES) stents in pulmonary vein stenosis (PVS).

Background: PVS is a serious condition with frequent restenosis after surgical and percutaneous interventions. After experiencing encouraging results with DES, we sought to compare outcomes of BMS and DES in native and post-surgical PVS.

Methods and results: A retrospective review of all patients who underwent stent implantation between 08/93 and 11/17 for PVS at Texas Children's Hospital was performed. BMS were used to treat 58 lesions in 37 patients and 105 DES used to treat 105 lesions in 41 patients. Mean age at first stent implant was 2.9 ± 3.5 years in BMS and 16.2 ± 18.8 months in DES group. Of those with follow-up catheterization, mean lumen loss rate from stent implant to first follow-up catheterization was 0.85 ± 1.47 mm/month over 6.4 ± 6.4 months in the BMS group (n = 44 lesions) compared to 0.16 ± 0.31 mm/month over 6.8 ± 7.4 months in the DES group (n = 86 lesions), p < .01. Follow-up for the BMS group was 14 months (6 days-22.3 years), with 13 mortalities, eight lesions were re-stented and six complete occlusions were noted. Follow-up for DES group (including four cross-overs) was 17.5 months (3 days-9 years), with 10 mortalities, seven lesions were re-stented, 11 had complete occlusion, 20 new adjacent lesions in the same vessel underwent stenting and 12 stents were intentionally fractured.

Conclusion: DES have significantly lowered lumen loss rate when compared to BMS at medium term follow-up and can be fractured to enable larger diameters. Availability of larger diameter DES would be ideal.

Keywords: congenital heart disease; pediatric intervention; pediatrics; stent restenosis.

Publication types

  • Comparative Study

MeSH terms

  • Age Factors
  • Child
  • Child, Preschool
  • Drug-Eluting Stents*
  • Endovascular Procedures / adverse effects
  • Endovascular Procedures / instrumentation*
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Metals*
  • Prosthesis Design
  • Pulmonary Veins / diagnostic imaging
  • Pulmonary Veins / physiopathology*
  • Recurrence
  • Retrospective Studies
  • Risk Factors
  • Stenosis, Pulmonary Vein / diagnostic imaging
  • Stenosis, Pulmonary Vein / physiopathology
  • Stenosis, Pulmonary Vein / therapy*
  • Stents*
  • Texas
  • Time Factors
  • Treatment Outcome
  • Vascular Patency

Substances

  • Metals